{"id":"lyrica-low-dose","safety":{"commonSideEffects":[{"rate":"20–30","effect":"Dizziness"},{"rate":"15–25","effect":"Somnolence"},{"rate":"5–10","effect":"Dry mouth"},{"rate":"5–10","effect":"Edema (peripheral)"},{"rate":"5–10","effect":"Weight gain"},{"rate":"3–7","effect":"Blurred vision"},{"rate":"3–5","effect":"Ataxia"}]},"_chembl":{"chemblId":"CHEMBL2108580","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By binding to presynaptic calcium channels, pregabalin decreases calcium influx and subsequently reduces the release of glutamate, noradrenaline, and substance P. This modulation of neurotransmitter release dampens neuronal hyperexcitability, making it effective for neuropathic pain and seizure disorders. The low-dose formulation maintains the same mechanism but at reduced systemic exposure.","oneSentence":"Pregabalin binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, reducing the release of excitatory neurotransmitters.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:49:37.997Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Neuropathic pain (diabetic peripheral neuropathy, postherpetic neuralgia)"},{"name":"Partial-onset seizures (adjunctive therapy)"},{"name":"Fibromyalgia"},{"name":"Generalized anxiety disorder"}]},"trialDetails":[{"nctId":"NCT07456761","phase":"NA","title":"Effect of Low-dose Pregabalin Retard (82.5 mg) Versus Standard-dose Pregabalin Retard (165 mg) on Postoperative Pain and Opioid Consumption After Elective Laparoscopic Abdominal Surgery: a Randomized, Double-blind, Controlled Trial","status":"NOT_YET_RECRUITING","sponsor":"South Egypt Cancer Institute","startDate":"2026-04","conditions":"Laparoscopic Abdominal Surgeries","enrollment":80},{"nctId":"NCT07377721","phase":"PHASE1","title":"A Study of HRS-2129 in Patients With Diabetic Peripheral Neuropathic Pain","status":"NOT_YET_RECRUITING","sponsor":"Shandong Suncadia Medicine Co., Ltd.","startDate":"2026-02","conditions":"Diabetic Peripheral Neuropathic Pain","enrollment":168},{"nctId":"NCT00659035","phase":"","title":"Use of Driving Tests to Evaluate Patient Performance on Oral Opioids","status":"ACTIVE_NOT_RECRUITING","sponsor":"Asokumar Buvanendran","startDate":"2008-04","conditions":"Chronic Pain","enrollment":450},{"nctId":"NCT05660538","phase":"PHASE2","title":"Evaluation of Efficacy and Safety of VX-548 for Painful Diabetic Peripheral Neuropathy (DPN)","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2022-12-20","conditions":"Diabetic Peripheral Neuropathy","enrollment":194},{"nctId":"NCT07016451","phase":"EARLY_PHASE1","title":"Efficacy of Low-Intensity Shockwave Therapy in Treating Radiation Cystitis","status":"ENROLLING_BY_INVITATION","sponsor":"Thanakrit Visuthikosol","startDate":"2024-04-02","conditions":"Radiation Cystitis","enrollment":40},{"nctId":"NCT06967363","phase":"","title":"Multimodal Imaging and Biospecimen Collection for Low Back Pain (LBPB)","status":"NOT_YET_RECRUITING","sponsor":"Peking University Third Hospital","startDate":"2025-05-15","conditions":"Chronic Low Back Pain (CLBP), Acute Low Back Pain, Low Back Pain","enrollment":360},{"nctId":"NCT06516094","phase":"PHASE3","title":"Efficacy and Safety in the Combination of Celecoxib / Pregabalin / Vitamin B for Low Back Chronic Pain","status":"COMPLETED","sponsor":"Laboratorios Silanes S.A. de C.V.","startDate":"2024-04-11","conditions":"Chronic Low-back Pain","enrollment":192},{"nctId":"NCT06155916","phase":"NA","title":"Sleep and Neuropathic Pain - Intervention Study on Pregabalin","status":"RECRUITING","sponsor":"Helsinki University Central Hospital","startDate":"2022-11-22","conditions":"Neuropathic Pain, Insomnia, Sleep Disorder","enrollment":40},{"nctId":"NCT06488586","phase":"","title":"IV Ketamine Vs. in Esketamine for MDD TRD","status":"RECRUITING","sponsor":"Gustavo Vazquez","startDate":"2023-03-20","conditions":"Treatment Resistant Depression","enrollment":80},{"nctId":"NCT06401499","phase":"PHASE4","title":"The Effect of Pregabalin and Etoricoxib on Pain Alone Versus in Combination","status":"NOT_YET_RECRUITING","sponsor":"Muhammad Ilyas","startDate":"2024-06-01","conditions":"Back Pain Lower Back Chronic","enrollment":140},{"nctId":"NCT04990804","phase":"PHASE4","title":"Opioid Free vs. Standard Perioperative Pain Regimen for Anterior Cervical Discectomy and Fusion (ACDF) Surgery","status":"TERMINATED","sponsor":"Vanderbilt University Medical Center","startDate":"2021-08-01","conditions":"Opioid Use, Spinal Diseases, Surgery--Complications","enrollment":8},{"nctId":"NCT04599894","phase":"PHASE4","title":"Reducing Postoperative Side Effect of Pregabalin","status":"COMPLETED","sponsor":"The First Hospital of Jilin University","startDate":"2020-11-01","conditions":"Pain, Postoperative, Arthroplasty, Replacement, Knee, Arthroplasty, Replacement, Hip","enrollment":58},{"nctId":"NCT01838044","phase":"PHASE4","title":"Efficacy and Safety Study of Celecoxib and Pregabalin Compared With Celecoxib Monotherapy, in Patients With Chronic Low Back Pain Having a Neuropathic Component","status":"TERMINATED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2013-10","conditions":"Chronic Low Back Pain With a Neuropathic Component","enrollment":180},{"nctId":"NCT01257529","phase":"PHASE1","title":"An Investigation Of The Absorption And Pharmacokinetics Of A Single Dose Of A Controlled Release (CR) Pregabalin Tablet Following A Low, Medium, And High-Fat Evening Meal As Compared To A Single Dose Of The Immediate Release (IR) Pregabalin Capsule In Healthy Volunteers","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2011-03","conditions":"Healthy","enrollment":28},{"nctId":"NCT01298466","phase":"PHASE4","title":"Primary Care Identification Of Patients With Chronic Neuropathic Low Back Pain Study","status":"WITHDRAWN","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2012-02","conditions":"Low Back Pain, Neuralgia","enrollment":""},{"nctId":"NCT03691038","phase":"NA","title":"Comparison of Conventional Dose Regimen and New Dose Regimen of Pregabalin","status":"TERMINATED","sponsor":"Kangbuk Samsung Hospital","startDate":"2018-10-10","conditions":"Pain, Neuropathic","enrollment":10},{"nctId":"NCT01504412","phase":"PHASE2","title":"Asian Phase 2 Study for Treatment of Pain Associated With Diabetic Peripheral Neuropathy","status":"COMPLETED","sponsor":"Daiichi Sankyo Co., Ltd.","startDate":"2012-01","conditions":"Pain, Diabetic Peripheral Neuropathy","enrollment":450},{"nctId":"NCT01352741","phase":"PHASE4","title":"Comparison of Increasing Doses of Tapentadol Versus a Combination of Tapentadol and Pregabalin","status":"COMPLETED","sponsor":"Grünenthal GmbH","startDate":"2011-03","conditions":"Low Back Pain, Neuropathic Pain","enrollment":622},{"nctId":"NCT01591980","phase":"PHASE4","title":"Effects of Perioperative Pregabalin for Post-Craniotomy Pain","status":"WITHDRAWN","sponsor":"Unity Health Toronto","startDate":"2013-08","conditions":"Chronic Postoperative Pain, Headache","enrollment":""},{"nctId":"NCT01863810","phase":"PHASE3","title":"Efficacy and Safety of KW21052 Compared to Lyrica in the Diabetic Patients With Neuropathic Pain","status":"UNKNOWN","sponsor":"KunWha Pharmaceutical Co., Ltd.","startDate":"2013-08","conditions":"Diabetic Neuropathy","enrollment":394}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":94,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Lyrica (low dose)","genericName":"Lyrica (low dose)","companyName":"KunWha Pharmaceutical Co., Ltd.","companyId":"kunwha-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pregabalin binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, reducing the release of excitatory neurotransmitters. Used for Neuropathic pain (diabetic peripheral neuropathy, postherpetic neuralgia), Partial-onset seizures (adjunctive therapy), Fibromyalgia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}